Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aligos Therapeutics Inc ALGS

Healthcare Biotechnology
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug... see more

Recent & Breaking News (NDAQ:ALGS)

Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference

GlobeNewswire June 10, 2021

Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 20, 2021

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results

GlobeNewswire May 10, 2021

Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021

GlobeNewswire May 5, 2021

Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors

GlobeNewswire April 27, 2021

Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study

GlobeNewswire April 14, 2021

Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

GlobeNewswire March 23, 2021

Aligos Therapeutics Begins Dosing with STOPS(TM) Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study

GlobeNewswire March 10, 2021

Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections

GlobeNewswire March 8, 2021

Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver

GlobeNewswire February 3, 2021

Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2021

Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020

GlobeNewswire December 17, 2020

Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH

GlobeNewswire December 7, 2020

Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD's The Liver Meeting Digital Experience(TM) 2020

GlobeNewswire November 16, 2020

Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

GlobeNewswire November 13, 2020

Aligos Therapeutics is awarded Euro1.8M VLAIO grant to advance chronic hepatitis B research

GlobeNewswire November 12, 2020

Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B

GlobeNewswire October 30, 2020

Aligos Therapeutics Announces Pricing of Initial Public Offering

GlobeNewswire October 15, 2020